(Q36168701)

English

Successful erlotinib treatment for a patient with gefitinib-related hepatotoxicity and lung adenocarcinoma refractory to intermittently administered gefitinib

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

0 references

Successful erlotinib treatment for a patient with gefitinib-related hepatotoxicity and lung adenocarcinoma refractory to intermittently administered gefitinib (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1 reference

based on heuristic

inferred from title

author name string

Tatsuya Nagano

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Yoshikazu Kotani

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Kazuyuki Kobayashi

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Masahiro Katsurada

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Yukihisa Hatakeyama

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Suya Hori

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Daisuke Tamura

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Daisuke Kasai

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Yasuhiro Funada

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Yoshihiro Nishimura

10

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

publication date

25 December 2011

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Case reports in pulmonology

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

2011

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

812972

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

copyright license

Creative Commons Attribution 3.0 Unported

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420486

1 October 2017

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420486

1 October 2017

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420486

1 October 2017

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420486

1 October 2017

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420486

1 October 2017

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420486

1 October 2017

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420486

1 October 2017

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420486

1 October 2017

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420486

1 October 2017

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420486

1 October 2017

EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F812972

21 January 2018

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F812972

21 January 2018

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F812972

21 January 2018

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F812972

21 January 2018

Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F812972

21 January 2018

Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F812972

21 January 2018

Successful gefitinib every other day administration in an advanced lung cancer patient with brain metastasis after gamma knife radiotherapy and chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420486

23 September 2018

Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations

1 reference

https://pubmed.ncbi.nlm.nih.gov/22937431

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/22937431

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22937431

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1155/2011/812972

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36168701&oldid=1801282626"